@article{8f912d88a8e841dab217f9e548dfff27,
title = "High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology",
abstract = "High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) is a newly defined entity in the latest World Health Organization Classification. Accurate diagnosis would appear to mandate fluorescence in situ hybridization (FISH) for all tumors with diffuse large B-cell lymphoma (DLBCL) morphology. We present the results of FISH, cell-of-origin, and immunohistochemistry (IHC) testing from 1228 DLBCL biopsies from 3 clinical trials and a population-based registry. HGBL-DH/TH made up 7.9% of the DLBCL, confined primarily to the germinal center B-cell–like (GCB; 13.3%) compared with activated B-cell-like (ABC; 1.7%) subtype (P < .001). HGBL-DH/TH with BCL2 rearrangement is a GCB phenomenon with no cases observed in 415 ABC DLBCL. A screening strategy restricting FISH testing to tumors of GCB subtype (by Lymph2Cx or Hans IHC) plus dual protein expression of MYC and BCL2 by IHC could limit testing to 11% to 14% of tumors, with a positive predictive value of 30% to 37%; however, this strategy would miss approximately one-quarter of tumors with HBGL-DH/TH with BCL2 rearrangement and one-third of all HGBL-DH/TH. These results provide accurate estimation of the proportion of HGBL-DH/TH among tumors with DLBCL morphology and allow determination of the impact of various methods available to screen DLBCL tumors for FISH testing.",
author = "Scott, {David W.} and King, {Rebecca L.} and Staiger, {Annette M.} and Susana Ben-Neriah and Aixiang Jiang and Heike Horn and Anja Mottok and Pedro Farinha and Slack, {Graham W.} and Daisuke Ennishi and Norbert Schmitz and Michael Pfreundschuh and Nowakowski, {Grzegorz S.} and Kahl, {Brad S.} and Connors, {Joseph M.} and Gascoyne, {Randy D.} and German Ott and Macon, {William R.} and Andreas Rosenwald",
note = "Funding Information: Conflict-of-interest disclosure: D.W.S has performed consultancy for Janssen and Celgene. B.S.K. has performed consulting for, and received research funding from, Genentech and Celgene. D.W.S., J.M.C., R.D.G., G.O., and A.R. are named inventors on a patent that has been licensed to NanoString Technologies. The remaining authors declare no competing financial interests. Funding Information: Studies performed at the British Columbia Cancer Agency were supported by a Project Program Grant from the Terry Fox Research Institute (1023) and funding from the British Columbia Cancer Foundation, Genome Canada, and Genome BC. A.M. was supported by research fellowships from the German Cancer Aid, the Michael Smith Foundation for Health Research, and Lymphoma Canada. A portion of this study was coordinated by the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (Peter J. O{\textquoteright}Dwyer and Mitchell D. Schnall, group cochairs) and supported by grants from the National Institutes of Health, National Cancer Institute (CA180820, CA180794, CA180790, CA180833, and CA180799). Publisher Copyright: {\textcopyright} 2018 by The American Society of Hematology",
year = "2018",
month = may,
day = "3",
doi = "10.1182/blood-2017-12-820605",
language = "English",
volume = "131",
pages = "2060--2064",
journal = "Blood",
issn = "0006-4971",
number = "18",
}